| Literature DB >> 36253775 |
Buffel Veerle1, Danhieux Katrien2, Philippe Bos3, Remmen Roy2, Van Olmen Josefien2, Wouters Edwin3.
Abstract
BACKGROUND: To assess the quality of integrated diabetes care, we should be able to follow the patient throughout the care path, monitor his/her care process and link them to his/her health outcomes, while simultaneously link this information to the primary care system and its performance on the structure and organization related quality indicators. However the development process of such a data framework is challenging, even in period of increasing and improving health data storage and management. This study aims to develop an integrated multi-level data framework for quality of diabetes care and to operationalize this framework in the fragmented Belgium health care and data landscape.Entities:
Keywords: Integrated Delivery Systems; Primary care; Quality of Healthcare; Routinely Collected Data; Type 2 Diabetes
Mesh:
Year: 2022 PMID: 36253775 PMCID: PMC9578257 DOI: 10.1186/s12913-022-08625-8
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.908
Fig. 1Flowchart of the phased approach of the development of the data framework and quality assessment tool
Dimensions of quality of care addressed by the integration of the chronic care model and cascade of care
| Dimension of quality of care | Theoretical approach | Measuring tool | Data level |
|---|---|---|---|
| Structure and organization | Chronic care model | ACIC-Sub scores: -Organization -Community linkages -Self-management support -Decision support -Delivery system design -Information systems | -Health system -Primary care practice |
| Process | Cascade of care approach | CoC bars: -tested -diagnosed -linked to care -taking treatment -followed up, | -Patient (individual level) |
| Outcomes | -under control |
Results of the assessment of the existing health data sources for T2D care
| Type | Collected/owned by | Period | Population | Content | Strengths | Limitations |
|---|---|---|---|---|---|---|
| Health Interview survey (HIS)a | Sciensano (Belgian Institute for Health) | Repeated cross-sectional: every 4 years since 1997 | Representative sample of the Belgian population (N = +/−10,000 respondents) | medication use, health care use and costs, health behavior (physical activity, diet, smoking, alcohol), BMI, diagnostic information | -Representative for the population -Extensive lifestyle and sociodemographic info | -Small numbers of T2D patients (6,2%) -Self-reported data, recall bias -Selection and sample bias -The most severe and institutionalized patients are excluded -Time lag: data of 2018 was available in 2021 -Cross-sectional data -No clinical data -No information about type of GP-practice |
| Belgian Health Examination study (BELHES)b | Cross-sectional: 2018 | Representative subsample of the HIS (N = +/1200 respondents) | blood and urine test, blood pressure measure, BMI | -Clinical data -Can be linked to HIS data | -Small sample (+ same limitations HIS data) | |
| Sentinel Network of General Practitioners (surveillance network)c | A network of Registered GPs, coordinated by Sciensano | Longitudinal: since 1979 Periodic modules to monitor one or more specific illness problems | A network of 125 practices (their patient population covers 1–1,5% of the Belgian population) | sociodemographics, treatment and morbidity data | -Representative for Belgian GP workforce -Able to study the evolution and epidemiology of certain diseases | -Quality of data strongly depends on the reporting quality of GPs -The most recent T2D module was in 2010 |
| Belgian Diabetes Register d | Diabetes Liga | Longitudinal: since 1997 | New patients < 40 years old diagnosed with T1D | sociodemographics, clinical data | -Clinical data -Longitudinal | -Only T1D patients (not the target population of this study) |
| IQED: Initiative for Quality Improvement & Epidemiology in Diabetes e | Hospital based data requested by Sciensano for audit (Surveillance of the convention for diabetes self-regulation) | Repeated cross-sectional retrospective study design (every 18 months): since 2001 | Patients in a diabetes care trajectory: +/− 100 diabetic centres treated +/− 120,000 patients -each time 10% of the population is sampled | clinical hospital data, socio-demographics, type of diabetes and complications, diabetes treatment, health examination data | -Clinical data -Focus on quality indicators -Based on principles of DiabCare | -Only type 1 and type 2 diabetic patients treated with 2 or more insulin injections per day (only a small part of the target population of this study) |
| Patients records f | GPs in their practices | Longitudinal: period depends on GP-practice | Patient-population of GP | Depending on GP (diagnostic info, health services, medication, health behavior, severity of diseases, comorbidities, familial anamnesis, RISC score, ….) | -Data can be very comprehensive (BMI, blood pressure, waist circumcise, smoking behavior, etc.) -Diagnostic, health care use, medication prescription and clinical data (GPs have easily access to the lab data of their patients) | -Several software systems: no standardized way of registration -Low reporting quality & large differences between practices -Difficult & time-consuming to extract the data (a lot of efforts for GPs and in particular if there is no administrative staff) -Data is not centralized |
Primary care registry based on patient records (Electronic Health Record) | Intego datag Computerized morbidity registration network of participating practices. | Longitudinal: since 1999 | Patient population of +/− 50 participating practices | Morbidity in primary care; diagnostic data, sociodemographic data, health care and medication data. The data is aimed to perform audits of the primary care. | -Representative for Flemish population -A lot of diagnostic and clinical longitudinal data -Large number of patients | -Currently Intego is in a transition phase and Medidoc (the software) does not longer exist: as a result no recent data is available -Quality of data depends on coding behaviour of clinicians and there is a lot of variation therein between GPs -Data from specialists as well as events that occur in hospital are not fully captured |
| Databases of the Intermutualistic Agency (IMA)h: Population database, Health care data &Pharmanet | gathered from the seven Belgian health insurance funds that manage compulsory health insurance | Longitudinal | Entire insured Population data (> 99% of the population) | sociodemographic data, health care and costs data, medication data (all reimbursed medication and health services), hospital visits (duration), etc. | -inexpensive compared to original data collections -population data - detailed health care data -Continuously collected -Standardized data registration -Linkage based on a unique identifier number is possible -Previously used in research on chronic care | -Not collected and designed for scientific purposes: not structured in readily available variables for analyses, -Lack of clinical and diagnostic information -No information about health behavior, BMI, etc. -Time lag: data is available in February year X of Year X – 2 |
| Data of the Medical laboratories | Laboratories (on request of GPs and specialists) | Depending on the lab | Each lab covers the patient population of several GPs/specialists/ hospitals | Clinical information (type and result value of test) | -Data extraction and linkage based on a unique identifier number is possible -Longitudinal data -Comprehensive clinical information | -Only clinical information −+/− 70 accredited labs -Several Lab information systems (LIS) |
Sources: ahttps://www.sciensano.be/en/projects/health-interview-survey-2018; bhttps://www.sciensano.be/en/projects/health-examination-survey; chttps://www.sciensano.be/en/network-general-practitionersdhttps://www.diabetes.be/belgisch-diabetes-register; ehttps://www.sciensano.be/en/projects/initiative-quality-improvement-and-epidemiology-diabetes;fhttps://www.ehealth.fgov.be/ehealthplatform/file/view/AWutmy6TnF_Mkwg-mMBj?filename=GP%20documentation%20-8th%20July%20%202019.pdf;ghttps://intego.be/nl/Welkom; hhttps://ima-aim.be/-Onze-databanken
The operationalization of the Cascade-of-Care
| Stage of CoC | Time (year) | Operationalization | Source | Reference | Remarks | |
|---|---|---|---|---|---|---|
| 1 | Tested | x-3 to x-1 (2015–17) | every 3 year a blood test on glucose/HbA1c | IMA | Domus Medica [ | Domus medica & IDF: from age 40 ideally combined with Findrisc (FINnisch Diabetes risc score) test (but this is not included in the data) CDC: from age 45 IDF: from age 40–45 |
| 2 | Diagnosed | x-1 (2017) | meeting the inclusion criteria: T2D medication or pre-diabetes pass in selection year (2017) Exclusion criteria: convention Type 1 diabetes and/or prescription insulin pump (only reimbursed for T1D) (in selection year or previous year) | IMA | [ | Using validated proxies, as we work with insurance data. T2D medication = Metformin, Sulfonylurea, Insulin Pre-diabetes pass = provides a better framework of care for pre-diabetes patients (including reimbursement of yearly four diabetes education consults provided by a dietician, diabetes educator, nurse, pharmacist, or physiotherapist) To exclude as good as possible type 1 diabetes patients, we also have two exclusion criteria. |
| 3 | In care | x-1 (2017) | At least one GP visit (in selection year) | IMA | IDF [ | As for patients in a capitation system GP-visits are not registered, an alternative measure is used for this group: “at least one medication or lab test prescription of a GP in selection year 2017” (as sensitivity analysis: using this indicator also for non-capitation patients and comparing with the other indicator) |
| 4 | In treatment | x (2018) | T2D medication in 2018 or, among patients in pre-diabetes trajectory, at least one T2D education or dietician consult | IMA | Domus Medica [ | For patients in a prediabetes care trajectory an annual consult with a diabetes educator and dietician is reimbursed. |
| 5 | Follow up | x to x + 1 (2018–19) | IMA/Lab-data | IDF [ | Once ‘AND’ (meeting all criteria) and once indicator specific (i.e. % that meets each criteria separately) | |
| > = 2 HbA1c measurements (at least one in 6 months) | Process indicator of QoC OECD: Percentage of patients with one or more HbA1c tests annually | |||||
| annual lipid profile measurement | to prevent additional cardiovascular disease (estimating cardiovascular risk) Process indicator OECD diabetes QoC: LDL cholesterol test annually | |||||
| annual microalbuminuria measure | To control kidney function | |||||
| annual creatinine measurement (and eGFR calculated) | To detect additional complications (diabetic nephropathy) | |||||
| annual food examination | To detect additional complications (neuropathy & foot complications) | |||||
| annual consultation by an ophthalmologist | IDF [ SIGN [ | To detect additional complications (retinopathy) | ||||
| 6 | Under control | x + 1 (2019) | HbA1c < 53 mmol/mol | Lab-data | IDF [ | Exploring whether we can stratify by ‘totally not under control’; ‘just not under control’; ‘just under control’; ‘well under control’ |
Fig. 2Entity-Relationship Diagram of the Multilevel database of the SCUBY project
Fig. 3Fictive visualization of the quality indicators of integrated T2D care stratified by primary care practice type